Overview

Useful For
Supporting a diagnosis of mucoepidermoid carcinoma

Reflex Tests

<table>
<thead>
<tr>
<th>Test Id</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>_PBCT</td>
<td>Probe, +2</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>_PADD</td>
<td>Probe, +1</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>_PB02</td>
<td>Probe, +2</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>_PB03</td>
<td>Probe, +3</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>_IL25</td>
<td>Interphases, &lt;25</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>_I099</td>
<td>Interphases, 25-99</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>_I300</td>
<td>Interphases, &gt;=100</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
</tbody>
</table>

Testing Algorithm
This test does not include a pathology consultation. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered and the appropriate FISH test will be ordered and performed at an additional charge.

This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results.

Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.

Method Name
Fluorescence In Situ Hybridization (FISH)

NY State Available
Yes

Specimen

Specimen Type
Tissue

Necessary Information
1. A pathology report is required in order for testing to be performed. Acceptable pathology reports include working


**Test Definition: MAMLF**

MAML2 (11q21) Rearrangement, Mucoepidermoid Carcinoma (MEC), FISH, Tissue

---

drafts, preliminary pathology or surgical pathology reports.

2. **A reason for testing must be provided**. If this information is not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.

**Specimen Required**

Submit only 1 of the following specimens:

- **Specimen Type:** Tissue
- **Preferred:** Tissue block
- **Container/Tube:** Formalin-fixed, paraffin-embedded (FFPE) tumor tissue block.
- **Collection Instructions:** Blocks prepared with alternative fixation methods may be acceptable; provide fixation method used.

- **Acceptable:** Slides
- **Specimen Volume:** Four consecutive, unstained, 5 micron-thick sections placed on positively charged slides and 1 hematoxylin and eosin-stained slide.

**Forms**

If not ordering electronically, complete, print, and send an **Oncology Test Request** (T729) with the specimen.

**Specimen Minimum Volume**

Two consecutive, unstained, 5-micron-thick sections placed on positively charged slides, and 1 hematoxylin and eosin-stained slide.

**Reject Due To**

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

**Specimen Stability Information**

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue</td>
<td>Ambient (preferred)</td>
<td>0 hours</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Refrigerated</td>
<td>0 hours</td>
<td></td>
</tr>
</tbody>
</table>

**Clinical & Interpretive**

**Clinical Information**

Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland neoplasm, representing over 30% of all malignant salivary gland tumors. The diagnosis of MEC can be quite challenging due to the degree of histologic overlap with other glandular, clear cell, or oncocytic salivary gland tumors. MAML2 rearrangements are detectable in 80% to 85% of MEC, but not in morphologic mimics such as oncocytic cystadenoma, Warthin tumor, oncocytoma, oncocytic carcinoma, acinic cell carcinoma, and metastatic renal cell carcinoma.
Reference Values
An interpretive report will be provided.

Interpretation
A neoplastic clone is detected when the percent of cells with an abnormality exceeds the normal cutoff for the MAML2 probe.

A positive result is consistent with a diagnosis of mucoepidermoid carcinoma (MEC).

A negative result suggests no rearrangement of the MAML2 gene region at 11q21. However, this result does not exclude the diagnosis of MEC.

Cautions
This test is not approved by the US Food and Drug Administration and it is best used as an adjunct to existing clinical and pathologic information.

Fixatives other than formalin (eg Prefer, Bouin) may not be successful for FISH assays, however nonformalin-fixed samples will not be rejected.

Paraffin-embedded tissues that have been decalcified are generally unsuccessful for FISH analysis. The pathologist reviewing the hematoxylin and eosin-stained slide may find it necessary to cancel testing.

Supportive Data
FISH analysis was performed on 28 mucoepidermoid carcinoma (MEC) formalin-fixed paraffin-embedded tissue samples and 51 control specimens. The normal controls were used to generate a normal cutoff for this assay. A rearrangement of MAML2 was identified in 26 of 28 (93%) MEC cases.

Clinical Reference

Performance
Method Description
The test is performed using a laboratory-developed MAML2 (11q21) dual-color break-apart strategy probe (BAP). Formalin-fixed paraffin-embedded tissues are cut at 5 microns and mounted on positively charged glass slides. The
selection of tissue and the identification of target areas on the hematoxylin and eosin (H and E)-stained slide is performed by a pathologist. Using the H and E-stained slide as a reference, target areas are etched with a diamond-tipped etcher on the back of the unstained slide to be assayed. The probe set is hybridized to the appropriate target areas and 2 technologists each analyze 50 interphase nuclei (100 total) with the results expressed as the percent of abnormal nuclei.(Unpublished Mayo method)

PDF Report
No

Day(s) Performed
Monday through Friday

Report Available
7 to 10 days

Specimen Retention Time
Slides and H&E used for analysis are retained by the laboratory in accordance to CAP and NYS requirements. Client provided paraffin blocks and extra unstained slides (if provided) will be returned after testing is complete.

Performing Laboratory Location
Rochester

Fees & Codes

 Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
88271x2, 88291-DNA probe, each (first probe set), Interpretation and report
88271x2-DNA probe, each; each additional probe set (if appropriate)
88271x1-DNA probe, each; coverage for sets containing 3 probes (if appropriate)
88271x2-DNA probe, each; coverage for sets containing 4 probes (if appropriate)
88271x3-DNA probe, each; coverage for sets containing 5 probes (if appropriate)
88274 w/modifier 52-Interphase in situ hybridization, <25 cells, each probe set (if appropriate)
88274-Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)
Test Definition: MAMLF
MAML2 (11q21) Rearrangement, Mucoepidermoid Carcinoma (MEC), FISH, Tissue

<table>
<thead>
<tr>
<th>LOINC® Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test ID</strong></td>
</tr>
<tr>
<td>MAMLF</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th><strong>Test Result Name</strong></th>
<th><strong>Result LOINC® Value</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>54689</td>
<td>Result Summary</td>
<td>50397-9</td>
</tr>
<tr>
<td>54692</td>
<td>Interpretation</td>
<td>69965-2</td>
</tr>
<tr>
<td>54691</td>
<td>Result</td>
<td>62356-1</td>
</tr>
<tr>
<td>54918</td>
<td>Specimen</td>
<td>31208-2</td>
</tr>
<tr>
<td>54694</td>
<td>Source</td>
<td>31208-2</td>
</tr>
<tr>
<td>54695</td>
<td>Tissue ID</td>
<td>80398-1</td>
</tr>
<tr>
<td>54696</td>
<td>Released By</td>
<td>18771-6</td>
</tr>
<tr>
<td>CG930</td>
<td>Reason For Referral</td>
<td>42349-1</td>
</tr>
<tr>
<td>55136</td>
<td>Method</td>
<td>85069-3</td>
</tr>
<tr>
<td>55137</td>
<td>Additional Information</td>
<td>48767-8</td>
</tr>
<tr>
<td>53394</td>
<td>Disclaimer</td>
<td>62364-5</td>
</tr>
</tbody>
</table>